Tyrosine kinase inhibitorFDA-approvedSecond-line

Erlotinib

How it works

Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.

Cancer types

Lung CancerEGFR-mutated

Efficacy

Studies show that erlotinib can improve response rates in patients with EGFR-mutated non-small cell lung cancer, with an objective response rate of approximately 70%.

Side effects

Moderate

Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.

Evidence from research

StudyCancer typeStageEfficacy
New Injectable Formulation for Lung Cancer TreatmentLung Cancerlab-studySource →
New Biomarker Identified for Lung Cancer Treatment ResponseLung Cancerlab-studySource →
Gemcitabine, Dasatinib, and Erlotinib in Treating Advanced Pancreatic CancerPancreatic Cancerphase-1Source →
Combination Therapy Shows Promise for Lung Cancer PatientsLung CancerobservationalThe median overall survival was 35.6 months, resulting in 77.8% at a 2-year survival rate.Source →
New Study Compares Cancer Treatments for Lung Cancer PatientsLung Cancermeta-analysisOsimertinib resulted in significantly longer overall survival compared to erlotinib-based regimens (HR for OS vs. erlotinib: 1.59, 95% CI 1.09-2.31).Source →
Combining Gemcitabine and Erlotinib May Improve Pancreatic Cancer TreatmentPancreatic Cancermeta-analysisGem-Erlo significantly improved disease control rate (DCR) [odds ratio (OR) =1.74; 95% confidence interval (CI): 1.03 to 2.92; P=0.04].Source →
Combining Cancer Drugs May Help Treat Lung CancerLung Cancerlab-studySource →
Erlotinib Resistance in Lung Cancer: New InsightsLung Cancerlab-studySource →
Zebrafish Study Identifies Erlotinib as Potential Wnt Inhibitor for LeukemiaLeukemialab-studyErlotinib treatment reduced self-renewal in human T-cell Acute Lymphoblastic Leukemia cells.Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.